Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine

Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by the novel coronavirus called SARS-CoV-2. There is a gap in our understanding regarding the immunopathogenesis of COVID-19. However, many clinical trials are underway across the world for screening effective drugs against...

Full description

Autores:
Tipo de recurso:
Article of investigation
Fecha de publicación:
2020
Institución:
Universidad de Bogotá Jorge Tadeo Lozano
Repositorio:
Expeditio: repositorio UTadeo
Idioma:
eng
OAI Identifier:
oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/12326
Acceso en línea:
https://doi.org/10.1016/j.intimp.2020.106928
http://hdl.handle.net/20.500.12010/12326
Palabra clave:
COVID-19
SARS-CoV-2
Immunopathogenesis
Vaccines
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
Rights
License
Acceso restringido
id UTADEO2_ffd50e357c451191c8a60ab8cbf91e6c
oai_identifier_str oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/12326
network_acronym_str UTADEO2
network_name_str Expeditio: repositorio UTadeo
repository_id_str
dc.title.spa.fl_str_mv Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
title Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
spellingShingle Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
COVID-19
SARS-CoV-2
Immunopathogenesis
Vaccines
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
title_short Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
title_full Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
title_fullStr Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
title_full_unstemmed Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
title_sort Overview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine
dc.subject.spa.fl_str_mv COVID-19
SARS-CoV-2
Immunopathogenesis
Vaccines
topic COVID-19
SARS-CoV-2
Immunopathogenesis
Vaccines
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
dc.subject.lemb.spa.fl_str_mv Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
description Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by the novel coronavirus called SARS-CoV-2. There is a gap in our understanding regarding the immunopathogenesis of COVID-19. However, many clinical trials are underway across the world for screening effective drugs against COVID-19. Nevertheless, currently, no proven effective therapies for this virus exists. The vaccines are deemed as a significant part of disease prevention for emerging viral diseases, since, in several cases, other therapeutic choices are limited or non‐existent, or that diseases result in such an accelerated clinical worsening that the efficacy of treatments is restricted. Therefore, effective vaccines against COVID-19 are urgently required to overcome the tremendous burden of mortality and morbidity correlated with SARS-CoV-2. In this review, we will describe the latest evidence regarding outstanding vaccine approaches and the challenges for vaccine production.
publishDate 2020
dc.date.accessioned.none.fl_str_mv 2020-08-26T17:27:14Z
dc.date.available.none.fl_str_mv 2020-08-26T17:27:14Z
dc.date.created.none.fl_str_mv 2020
dc.type.local.spa.fl_str_mv Artículo
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
format http://purl.org/coar/resource_type/c_2df8fbb1
dc.identifier.issn.spa.fl_str_mv 1567-5769
dc.identifier.other.spa.fl_str_mv https://doi.org/10.1016/j.intimp.2020.106928
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12010/12326
dc.identifier.doi.spa.fl_str_mv https://doi.org/10.1016/j.intimp.2020.106928
identifier_str_mv 1567-5769
url https://doi.org/10.1016/j.intimp.2020.106928
http://hdl.handle.net/20.500.12010/12326
dc.language.iso.spa.fl_str_mv eng
language eng
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_f1cf
dc.rights.local.spa.fl_str_mv Acceso restringido
rights_invalid_str_mv Acceso restringido
http://purl.org/coar/access_right/c_f1cf
dc.format.extent.spa.fl_str_mv 45 páginas
dc.format.mimetype.spa.fl_str_mv image/jepg
dc.publisher.spa.fl_str_mv International Immunopharmacology
dc.source.spa.fl_str_mv reponame:Expeditio Repositorio Institucional UJTL
instname:Universidad de Bogotá Jorge Tadeo Lozano
instname_str Universidad de Bogotá Jorge Tadeo Lozano
institution Universidad de Bogotá Jorge Tadeo Lozano
reponame_str Expeditio Repositorio Institucional UJTL
collection Expeditio Repositorio Institucional UJTL
bitstream.url.fl_str_mv https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/1/Captura.PNG
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/3/Overview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdf
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/2/license.txt
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/4/Captura.PNG
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/5/Overview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdf.jpg
bitstream.checksum.fl_str_mv 7e8d822a41004d203655052198b1dff3
eccfca9470d95b67801b4a03986b55df
abceeb1c943c50d3343516f9dbfc110f
7e8d822a41004d203655052198b1dff3
d7ba685b924cf1ce97a2a7d7e825d6f6
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional - Universidad Jorge Tadeo Lozano
repository.mail.fl_str_mv expeditio@utadeo.edu.co
_version_ 1812100335561342976
spelling 2020-08-26T17:27:14Z2020-08-26T17:27:14Z20201567-5769https://doi.org/10.1016/j.intimp.2020.106928http://hdl.handle.net/20.500.12010/12326https://doi.org/10.1016/j.intimp.2020.106928Coronavirus disease 2019 (COVID-19) is a pandemic infectious disease caused by the novel coronavirus called SARS-CoV-2. There is a gap in our understanding regarding the immunopathogenesis of COVID-19. However, many clinical trials are underway across the world for screening effective drugs against COVID-19. Nevertheless, currently, no proven effective therapies for this virus exists. The vaccines are deemed as a significant part of disease prevention for emerging viral diseases, since, in several cases, other therapeutic choices are limited or non‐existent, or that diseases result in such an accelerated clinical worsening that the efficacy of treatments is restricted. Therefore, effective vaccines against COVID-19 are urgently required to overcome the tremendous burden of mortality and morbidity correlated with SARS-CoV-2. In this review, we will describe the latest evidence regarding outstanding vaccine approaches and the challenges for vaccine production.45 páginasimage/jepgengInternational Immunopharmacologyreponame:Expeditio Repositorio Institucional UJTLinstname:Universidad de Bogotá Jorge Tadeo LozanoCOVID-19SARS-CoV-2ImmunopathogenesisVaccinesSíndrome respiratorio agudo graveCOVID-19SARS-CoV-2CoronavirusOverview of the current promising approaches for the development of an ef- fective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccineArtículohttp://purl.org/coar/resource_type/c_2df8fbb1Acceso restringidohttp://purl.org/coar/access_right/c_f1cfMirzaei, RasoulMohammadzadeh, RokhsarehMahdavi, FarzadBadrzadeh, FaribaKazemi, SheidaEbrahimi, MehdiSoltani, FatemehKazemi, SimaSalimi Jeda, AliDarvishmotevalli, MohammadYousefimashouf, RasoulKeyvani, HosseinKarampoor, SajadORIGINALCaptura.PNGCaptura.PNGVer portadaimage/png150206https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/1/Captura.PNG7e8d822a41004d203655052198b1dff3MD51open accessOverview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdfOverview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdfArtículo reservadoapplication/pdf1281025https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/3/Overview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdfeccfca9470d95b67801b4a03986b55dfMD53embargoed access|||2200-08-26LICENSElicense.txtlicense.txttext/plain; charset=utf-82938https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/2/license.txtabceeb1c943c50d3343516f9dbfc110fMD52open accessTHUMBNAILCaptura.PNGCaptura.PNGPortadaimage/png150206https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/4/Captura.PNG7e8d822a41004d203655052198b1dff3MD54open accessOverview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdf.jpgOverview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdf.jpgIM Thumbnailimage/jpeg11722https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/12326/5/Overview-of-the-current-promising-approaches-for-the-devel_2020_Internationa.pdf.jpgd7ba685b924cf1ce97a2a7d7e825d6f6MD55open access20.500.12010/12326oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/123262020-08-26 12:29:12.815open accessRepositorio Institucional - Universidad Jorge Tadeo Lozanoexpeditio@utadeo.edu.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